Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 20/20 | 0.58 |
| ▸ | HCRTR1 | O43613 | 15/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17830177 | 1.00 | HCRTR2 (0.58) | HCRTR2HCRTR1CYP3A4NR1I2ADRA2B | |
| SCHEMBL2904344 | 1.00 | HCRTR2 (0.58) | HCRTR2HCRTR1CYP3A4NR1I2ADRA2B | |
| SCHEMBL903254 | 1.00 | HCRTR2 (0.58) | HCRTR2HCRTR1CYP3A4NR1I2ADRA2B | |
| SCHEMBL12024777 | 0.88 | HCRTR1 (0.57) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL23018152 | 0.86 | HCRTR2 (0.62) | HCRTR2HCRTR1CYP3A4 | |
| Hydrochloric Acid SCHEMBL21612201 | 0.85 | HCRTR2 (0.54) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL19196928 | 0.85 | HCRTR1 (0.56) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL19196774 | 0.85 | HCRTR1 (0.56) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL2906415 | 0.85 | HCRTR2 (0.57) | HCRTR2HCRTR1 | |
| SCHEMBL2906417 | 0.85 | HCRTR2 (0.57) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177616-B1 | NOVEL ROUTES OF SYNTHESIS FOR THE PREPARATION OF SUVOREXANT | SANDOZ AG (CH) | 2021-02-24 | — | — | EP | disclosed |
| EP-3177616-B1 | NOVEL ROUTES OF SYNTHESIS FOR THE PREPARATION OF SUVOREXANT | SANDOZ AG (CH) | 2021-02-24 | — | — | EP | disclosed |
| US-10030010-B2 | Route of synthesis for the preparation of suvorexant | SANDOZ AG (CH) | 2018-07-24 | — | — | US | disclosed |
| US-10030010-B2 | Route of synthesis for the preparation of suvorexant | SANDOZ AG (CH) | 2018-07-24 | — | — | US | disclosed |
| US-10030010-B2 | Route of synthesis for the preparation of suvorexant | SANDOZ AG (CH) | 2018-07-24 | — | — | US | disclosed |
| US-20170217947-A1 | Novel Route of Synthesis for the Preparation of Suvorexant | SANDOZ AG (CH) | 2017-08-03 | — | — | US | disclosed |
| US-20170217947-A1 | Novel Route of Synthesis for the Preparation of Suvorexant | SANDOZ AG (CH) | 2017-08-03 | — | — | US | disclosed |
| US-20170217947-A1 | Novel Route of Synthesis for the Preparation of Suvorexant | SANDOZ AG (CH) | 2017-08-03 | — | — | US | disclosed |
| EP-3177616-A1 | NOVEL ROUTES OF SYNTHESIS FOR THE PREPARATION OF SUVOREXANT | Sandoz AG (CH) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016020404-A1 | PROCESS FOR THE RESOLUTION OF (R,S)-DIAZEPANE AND DIAZEPANONE DERIVATIVES | SANDOZ AG (CH) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016020404-A1 | PROCESS FOR THE RESOLUTION OF (R,S)-DIAZEPANE AND DIAZEPANONE DERIVATIVES | SANDOZ AG (CH) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016020405-A1 | NOVEL ROUTES OF SYNTHESIS FOR THE PREPARATION OF SUVOREXANT | SANDOZ AG (CH) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016020405-A1 | NOVEL ROUTES OF SYNTHESIS FOR THE PREPARATION OF SUVOREXANT | SANDOZ AG (CH) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016020406-A1 | NOVEL ROUTES OF SYNTHESIS FOR THE PREPARATION OF SUVOREXANT | SANDOZ AG (CH) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016020403-A1 | PREPARATION OF A BENZOIC ACID DERIVATIVE AND ITS USE FOR THE PREPARATION OF SUVOREXANT | SANDOZ AG (CH) | 2016-02-11 | — | — | WO | disclosed |
| EP-2049529-B1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20090192143-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-07-30 | — | — | US | disclosed |
| US-20090192143-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-07-30 | — | — | US | disclosed |
| US-20090192143-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-07-30 | — | — | US | disclosed |
| WO-2008008518-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217947-A1 | Novel Route of Synthesis for the Preparation of Suvorexant | CYP51A1, CYP3A5, HCRTR2 | HCRTR2 3/4885HCRTR1 5/4885CYP3A4 6/4885 |
| US-20090192143-A1 | Substituted diazepan orexin receptor antagonists | HCRTR2, HCRTR1, CRHR1 | HCRTR2 1/4885HCRTR1 2/4885CYP3A4 2856/4885 |
| US-10030010-B2 | Route of synthesis for the preparation of suvorexant | CYP51A1, CYP3A5, HCRTR2 | HCRTR2 3/4885HCRTR1 15/4885CYP3A4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.